Introduction
Double-blind placebo-controlled clinical trials have indicated that topical treatment of herpes simplex virus (HSV) lesions in man with cicloxolone sodium (CCX) or carbenoxolone (CBX) markedly reduce both healing time and pain associated with lesions (Poswillo & Roberts, 1981; Csonka & Tyrrell, 1984) . The anti-HSV activity of the drugs in vitro has been shown to be complex: quantitatively the synthesis, processing and transport of several viral gene products are affected so that the mode of action cannot be related specifically to a single viral protein. The anti-HSV effect is manifest principally at the level of particle assembly and maturation. Grown in the presence of these drugs, HSV particle yields are not only reduced, but more importantly exhibit a dramatically increased particle/p.f.u. ratio, indicating a pronounced loss of virus quality (as defined by relative infectivity) (Dargan & Subak-Sharpe, 1985 , 1986a Dargan et al., 1988) . In addition, a specific HSV genetic component, identified by a difference in sensitivity between HSV-1 and HSV-2, has been pinpointed to the locations of glycoproteins gH and gC by analysis of intertypic recombinants (Dargan & Subak-Sharpe, 1991) . The complex nature of the general antiviral activity against HSV suggested to us that the replication of viruses of unrelated groups might be similarly inhibited by the triterpenoid drugs. We were able to demonstrate that CCX does indeed possess broad range antiviral activity (Gait et al., 1990 ) and the total yield of viruses from several different families is adversely affected by the presence of CCX in the growth medium; in contrast, a togavirus is not affected.
Gait et al. (1990) assigned viruses to three CCX sensitivity classes (CCX s) based on the kinetics of the dose-response curves obtained. The first [including HSV-1, HSV-2, equine herpesvirus type 1, bovine herpesvirus type 1, influenza A virus and vesicular stomatitis virus (VSV)] exhibits a progressive dose-dependent reduction in infectious virus yield. The second (CCX~-2) (including Bunyamwera and Germiston bunyavirus; poliovirus type 1; reovirus type 3 and adenovirus type 5) showed biphasic kinetics, the doseresponse curve reaching a plateau of maximum antiviral effect. The third class (CCX~-3) [containing Semliki Forest virus (SFV)] appeared to be unaffected by the presence of CCX and at present contains only a togavirus. Dargan et al. (1992) have found that CCX impairs the release of infectious SFV (CCX~-3) from cells and have detailed the processes affected by CCX antiviral activity for four CCXs-2 class viruses. The present study investigates the antiviral activity of CCX against the negative-strand RNA virus VSV (CCXs-1) and compares the mechanism of antiviral action against VSV with that against HSV (CCX~-I).
Methods
Cells. BSC-1 cells were used throughout. Cells were grown in Eagle's MEM supplemented with 10~ foetal calf serum (EFC10) but when treated with CCX the serum was reduced to 2~ (EFC2). BSC-1 cells have been investigated previously by Gait et al. (1990) and found to show little cytotoxic effect at even 300 p.M: IC2o > 300 IXM after 48 h exposure.
Drugs. CCX (Biorex Laboratories) was prepared as described (Dargan & Subak-Sharpe, 1985) . Monensin (Mon) (Sigma) was prepared as a 10 mM stock solution in ethanol; tunicamycin (Tun) (Sigma) and actinomycin D (Act D) (Merck, Sharp and Dohme) were prepared as 1 mg/ml stocks in sterile distilled water.
Virus. VSV (Indiana serotype) was grown on BSC-1 cell layers infected at a multiplicity of 0.01 p.f.u./cell. After a 2 day incubation at 31 °C the VSV released into the growth medium was harvested and the yield titrated by plaque assay. VSV was purified by exactly the same method as described for HSV by Szilagyi & Cunningham (1991) . Labelled virus was prepared by infecting BSC-1 cells with 10 p.f.u. VSV/ceI1, then adding 25 [tCi/ml [3sS] methionine to the culture medium, with or without 150 ~tM-CCX, and incubating from 1 to 24 h at 37 °C. Virus particles were counted by negative staining in a Siemens 101 electron microscope using phosphotungstic acid, as described by Wildy et al. (1960) .
VSV CCX dose-response. Confluent monolayers of cells (2 x 106 cells) were infected with VSV at 5 p.f.u./cell and allowed to absorb for 1 h at 37 °C. The cell layer, after three washes with PBS supplemented with 5~ calf serum (PBS C5), was then overlaid with 2 ml EFC2 containing various concentrations of drug and incubated at 37 °C for 24 h. To determine total infectious yield the cells were scraped into the medium and then disrupted by ultrasound; where the yield was separated into cell-associated (CA) and cell-released (CR) components, the clarified supernatant medium provided the CR virus preparations, whereas the VSV liberated by sonicating the infected cell pellet (made to 2 ml with fresh EFC2) provided the CA virus preparation. The infectious progeny yield was estimated by plaque assay. To monitor any cytotoxic effect, uninfected cells were treated in parallel with CCX and cell viability was determined after 24 h (Dargan & Subak-Sharpe, 1985; Gait et al., 1990) .
One-step VSV growth curve. Confluent monolayers of 2 x 106 cells were infected with VSV at 5 p.f.u./cell; after the 1 h absorption and washing procedures they were overlaid with EFC2 with or without 300 ~tM-CCX. At various times post-infection (p.i.) the cultures were harvested, sonicated and the infectious yield was titrated.
Radiolabelling of cellular and VSV-specified polypeptides. Confluent monolayers in Linbro trays (5 x l0 s cells/well) were infected with 5 or 50 p.f.u./cell. After the absorption and washing procedures the cultures were overlaid with EFC2 [or EFC2 having one-fifth the normal concentration of methionine (Emet-FC2)] containing the indicated concentrations of CCX, Mon or Tun.
[35S]Methionine (10 p.Ci/ml; 900 Ci/mmol) or 10 IxCi/ml [14C]glucosamine hydrochloride (50 to 60 mCi/mmol) were added to the mock-infected (m.i.) or VSV-infeeted cultures in the presence or absence of various concentrations of the drugs.
SDS-PAGE.
Extraction of protein for SDS-PAGE and the conditions for electrophoresis were as described by Marsden et al. (1976) , except that 10% acrylamide gels were used.
Radiolabelling of RNA. BSC-1 cells (1 x 10 7) seeded onto 90 mm tissue culture dishes in EFClo lacking phosphate were incubated at 37 °C overnight. From 2 h prior to infection the cells were treated with 5 txg/ml Act D and either m.i. or infected with VSV at a multiplicity of 50 p.f.u./cell. VSV secondary transcripts from infected cells treated in the presence or absence of various concentrations of CCX were labelled with [32p]orthophosphate (25 pCi/ml) between 4 and 8 h p.i., and RNA was extracted as described (Johnson & Everett, 1986) . RNA similarly extracted from m.i. cells had been labelled between 1 and 24 h.
Preparation of RNA samples for agarose gel electrophoresis. The yield of RNA was estimated using the absorbance at 260 nm. For electrophoresis, 38.75 p.1 of sample buffer [5 ~tl, 10 x MOPS running buffer; 8-75 ktl formaldehyde (37~); 25 ~tl formamide] was added to 11.25 ~tl of RNA preparation and then 10 ktl of formaldehyde loading buffer (1 mM-EDTA pH 8.0, 0-25~ bromophenol blue, 0.25% xylene cyanol, 50~ glycerol) was added. Electrophoresis was through 1.2~ agarose/formaldehyde gels containing 1 ~ MOPS running buffer and 0.5% formamide. Electrophoresis was at 5 V/cm until the dye had migrated halfway down the gel. After soaking in water overnight the gel was stained with ethidium bromide (250 ~tg/ml) for 45 min and then photographed under u.v. illumination (260 nm), allowing visualization of the total RNA loaded into each gel track. Finally, the gel was dried and placed against X-Omat S film to provide an autoradiograph.
MOPS (10 x ) running buffer was prepared by adding 41.8 g MOPS to 800 ml diethylpyrocarbonate (DEPC)-treated H20 pH 7. DEPCtreated 3 M-sodium acetate (16"6 ml) and 20 ml DEPC-treated 0.5 M-EDTA pH 8 were then added and the total volume brought to 11 with DEPC-treated H20; the buffer was filtered before use.
Results
The effect of CCX on the VSV infectivity in the CR and CA virus yields was measured by dose-response experiments which showed progressive reduction in infectious virus yield: 24 h treatment with 300 IxM-CCX reduced the infectivity in the CA and CR components by 100-and 1000-fold respectively (Fig. 1) . The greater sensitivity of the CR yield suggests that increasing the concentration of CCX either delays virus replication or slows the release of progeny VSV from the infected cell, or results in inactivation of CR virus at a faster rate than that of virus which remains associated with the cell. One-step VSV growth curves performed in the presence or absence of 300 ~tM-CCX (Fig. 2) showed that drug treatment abolishes production of infectious virus progeny. Therefore, both a delay in virus replication and slower release of progeny from infected cells can be discounted as explanations.
To investigate whether CCX inhibited VSV replication at a specific stage during the virus replication cycle, CCX, to 300 O.M, was added to the growth medium of VSV-infected cells at 0, 2, 4, 6, 8, 10, 12, 14, 16 infectious yield was measured. Progressively later addition of drug, between 4 and 12 h p.i., revealed a near linear relationship between time of drug application and the loglo yield of infectious VSV at 24 h (Fig. 3) . By 12 h p.i. the virus replication cycle was completed ( Fig. 2 ) and later addition of CCX had little if any further effect on infectious yield (Fig. 3) . The curves obtained indicate that there is no specific point of blocking during the 24 h VSV replication cycle, and show that the drug impairs virus production throughout the growth period.
The effect of various concentrations of CCX on the 24 h yield of VSV particles, p.f.u, and particle :p.f.u. ratios for three independent experiments are detailed in Table  1 . The data consistently showed that increasing the CCX concentration results in a progressive reduction in infectivity (p.f.u.), accompanied by a smaller decrease in the number of particles visible by electron microscopy (EM) and a consequent increase in the particle:p.f.u. ratio. Table 2 shows a further experiment in which the total yield was separated into its CR and CA components. With increasing CCX concentration the progeny virus infectivity decreased more rapidly in the CR component. This was not simply due to failure to release budding virus particles, but rather because of loss of virus quality, shown by the greatly increased particle:p.f.u, ratio. Particle:p.f.u. ratios could not be calculated for the CA component at 100, 200 and 300 gM-CCX as the number of virus particles visible by EM was too low to be measured.
To investigate whether CCX has a virucidal effect, suspensions of VSV prepared in PBS C5 were incubated at 4 °C or 37 °C for 24 h with or without 300 ~tM-CCX and the infectivity was then assayed. Without the drug, VSV proved more stable at 4 °C than at 37 °C (79~ and 17~ of initial infectivity surviving respectively); the presence of 300 p,M-CCX further reduced infectious VSV 10-fold and sevenfold respectively. In repeated experiments the magnitude of this virucidal effect varied somewhat, but never by greater than 10-fold. We conclude that the virucidal effect cannot by itself account for the greater sensitivity of CR VSV to CCX ( Fig. 1 and Table 2 ). To examine whether growth of VSV in the presence of CCX gave rise to progeny virions having alterations in structural proteins, the 24 h yield of [35S]methioninelabelled virus purified from control, or 150 ~tM-or 300 ~tM-CCX-treated cells was studied by SDS-PAGE. No significant differences were detected in the VSV L, G, N, NS or M proteins between control and CCX-treated virus and nor did these experiments provide evidence that CCX increased the amount of defective interfering VSV (data not shown).
We investigated the effect of CCX treatment on the abundance of cytoplasmic RNA transcripts in m.i. and VSV-infected cells. VSV primary transcripts are synthesized by a viral transcriptase which is a component of the virus particle (Marcus et al., 1971) , whereas secondary transcripts, synthesized on progeny genomes by nascent transcriptase, depend upon protein synthesis. Primary and secondary transcripts are identical and consist of a leader RNA and five monocistronic mRNAs encoding five proteins, N, NS, M, G and L Freeman et al., 1977; Rhodes et al., 1977) . Transcriptional control regulates the quantity of each VSV protein made because VSV mRNAs are efficiently translated on host cell ribosomes (Villarreal et al., 1976) . Thus, the effect of CCX on each VSV transcript can be correlated with the amount of each protein made. VSV secondary transcripts, cellular transcripts and polypeptides in m.i. and VSV-infected cells were labelled in parallel with [32p]orthophosphate or [35S]methionine between 4 and 24 h p.i. Act D was used to selectively suppress host cell RNA synthesis when labelling VSV secondary transcripts.
The effect of CCX on the synthesis of VSV secondary transcripts is shown in Fig. 4 : with increasing CCX concentration VSV transcript synthesis progressively declined. Synthesis of the L transcript was no longer detectable with 100 gM-CCX (lane 2) and synthesis of the VSV transcripts was virtually undetectable with 300 gM-CCX (lane 4). Ethidium bromide staining of the gel showed that RNA loading differences could not account for the great reduction in the amount of VSV transcripts observed (data not shown). We concluded that treatment of infected cells with increasing CCX concentrations results in progressive dose-dependent reduction in the seen (1, 2, 3 and 4); these are also apparent in gel profiles published by others (Evans et al., 1979; Paterson, 1983) . The derivation of these polypeptides has not been studied and is unclear. The mobility of the G protein increased progressively with increasing CCX concentration (Fig. 6 ). Densitometry measurements from the gel showed that CCX alone resulted in L protein becoming undetectable with 200 O.M-CCX, whereas N polypeptide progressively decreased and G protein synthesis appeared to be affected only by 300 ttM-CCX. In contrast, NS and M protein synthesis were increased significantly by CCX. The presence of Act D reduced and then abolished the magnitude of the NS and M protein increases, whereas L, G and N proteins progressively decreased with CCX concentration. In similar experiments investigating the effect of CCX on VSV primary transcription, no viral transcripts were detected. As all viral proteins were made in substantial amounts (data not shown) it seems unlikely that CCX has a significant effect on VSV primary transcription.
In VSV-infected cells treated with 300 ~tM-CCX (Fig.  5) [35S]methionine, incorporation into protein was only reduced to 61% of the control level whereas the number of VSV particles decreased 100-fold (Table 1 and 2) . Thus, the data argue for CCX also having a strong inhibitory effect on VSV particle assembly.
Glycosylation of cellular (BHK and Flow 2002) and HSV glycoproteins is known to be strongly inhibited by CCX and CBX (Dargan & Subak-Sharpe, 1986a, b) , and Mon also inhibits glycosylation in the Golgi apparatus (Ledger & Tanzer, 1984; Boss et al., 1984) . Tun blocks addition of the first N-linked oligosaccharides to the nascent glycoprotein in the endoplasmic reticulum (Tkacz & Lampen, 1975 (Fig.  7a) . Densitometry demonstrated that 300 ktM-CCX caused an increase in G and M proteins by 385~ and 575~o respectively (Fig. 7b) . (Note that G and NS proteins behave, differently to Fig. 6 in this experiment.) In cultures treated with Mon, the amounts of L, N and NS proteins were virtually unchanged whereas those of G and M proteins were substantially increased ( Fig. 7a  and b) . With Tun, the amounts of L, N and NS proteins appeared to be unchanged, whereas the G and M proteins increased in a m o u n t ( Fig. 7a and b) . The different responses of the five virion proteins demonstrate that the effect is on virion c o m p o n e n t pools and not mature particles. The electrophoretic mobility of the G protein b a n d was increased with each drtig, suggesting an effect on oligosaccharide processing. In extracts treated with C C X (200 gM and 300 gM) and M o n (5 gM and 10 gM) the G protein b a n d ran to equivalent positions in the gel, but with Tun it exhibited even greater mobility, p i n p o i n t i n g the unglycosylated precursor position for the G glycoprotein (Fig. 7a) . The VSV G protein is the major b a n d that labels with [14C]glucosamine in infected cell extracts (Fig. 7 d) and the intensity of this b a n d increased m a r k e d l y with increasing C C X concentration (to 200 gM). This supports the [3SS]methionine d a t a (Fig. 7a) . In contrast to the strong inhibition of glycosylation in HSV-infected B H K and F l o w 2002 ceils ( D a r g a n & Subak-Sharpe, 1986a, b), the processing (Fig. 7d, lane 12) . Bearing in mind the results shown in Fig. 4 and 7, we concluded that the intracellular stability of the G protein is enhanced by CCX, Mon or Tun treatment. The electrophoretic mobility of the G protein increased suggesting reduced oligosaccharide processing with both CCX and Mort, whereas Tun blocks processing and only the unglycosylated G protein precursor is produced. Treatment with CCX, Mon and Tun appeared to result in similar relative responses at the polypeptide level (Fig. 7) , so we compared the effects of the three drugs on VSV particle number, infectious virus yield and the particle :p.f.u. ratio. Treatment of infected cells with 150 lZM-or 200 ~tM-CCX increased the VSV particle:p.f.u, ratio at least 10-fold (Table 3) , whereas Mon and Tun had no significant effect. This indicates (i) that glycosylation of the VSV G protein is not required for the production of fully infectious virus, consistent with the findings of Gibson et al. (1978) ; (ii) that assembly in the presence of CCX (but not Mon or Tun) results in reduced quality of the virus progeny; and (iii) reduced particle yield correlates with reduced glycosylation: this may be due to the drug's direct effect on G protein glycosylation or a drug effect on another function essential for particle formation.
Discussion
CCX is a potent inhibitor of VSV replication in BSC-1 cells. The 1000-to 10000-fold reduction in infectious VSV yield (Fig. I) in cultures treated for 24 h with 300 I.tM-CCX resembles the reduction in HSV infectious yield with this concentration of drug (Dargan & SubakSharpe, 1985) . The data concerning VSV particle number and particle :p.f.u. ratio demonstrate additional similarities in the antiviral effect of CCX for these two CCXs-1 class viruses (Table 1 ; Dargan & Subak-Sharpe, 1985) ; although one is an RNA and the other a DNA virus, the antiviral effect of CCX in each case operates both through inhibition of particle assembly and by a reduction of quality (average infectivity) of the virus progeny. SDS-PAGE studies have correlated CCXinduced loss of HSV infectivity with multiple quantitative changes in the HSV set of structural proteins (Dargan & Subak-Sharpe, 1986a) . The reduced quality of the infectious HSV virions made in the presence of CCX is supported by the demonstration of their greater thermolability (Dargan & Subak-Sharpe, 1986a) . With VSV we could not detect any differences in the polypeptide profile of virions produced with or without CCX. The virucidal effect of CCX reduces both VSV and HSV infectivity approximately 10-fold in 24 h at 4°C or 37 °C (Dargan & Subak-Sharpe, 1985) . The mechanism by which CCX elicits its virucidal effect has not been investigated; however, the drug is highly lipophilic (Symons & Parke, 1980) and probably interacts with the VSV and HSV envelope, so affecting adsorption and/or penetration.
The antiviral activity of CCX against VSV and HSV operates throughout the virus replication cycle, indicating that the drug does not accomplish its effect through the specific inhibition of any single essential virus gene product ( Fig. 3 ; Dargan & Subak-Sharpe, 1985) . VSV primary transcription does not appear to be significantly affected, but we found a rapid CCX dose-dependent reduction in the levels of all VSV secondary transcripts (Fig. 4) . Possible explanations are that the drug might block transport of RNA, inhibit the transcription process itself, or result in the synthesis of mRNAs with altered stability. As VSV replication is completely cytoplasmic, impaired transport of RNA cannot explain the levels of VSV transcripts, although it could account for the levels of cellular transcripts. CCX could influence the activity of the transcription process indirectly through mobilizing the cellular stress response (Fig. 6) , which involves vigorous stress protein mRNA transcription, and a concomitant inhibition of transcription and translation of other mRNAs (Ashburner & Bonner, 1979) . However, in cultures treated with both CCX and Act D, which abolishes the stress response, VSV secondary transcripts are reduced, so stress cannot furnish the full explanation. Nevertheless, under the usual conditions of infection, the CCX-induced stress response could play some role in reducing the levels of cell-and virus-specified transcripts. CCX did not affect the phosphorylation of cellular or VSV polypeptides detectably (data not shown). One possible explanation for the effect of CCX on the levels of cellular and VSV transcripts stems from the work of Mukherjee & Simpson (1987) on indomethacin. CCX and indomethacin could have equivalent effects on a cell membraneassociated transcription factor required for the transcriptase activity of the VSV nucleocapsid, as both CBX (Roberts & Taylor, 1980) and indomethacin alter the biosynthesis of prostaglandins which modify the transcription factor. Other possible explanations for the effi~ct of CCX on cytoplasmic transcripts include activation of RNases, activation of proteases resulting in degradation of the transcriptase complex, or binding of the drug to the transcriptase complex itself, thereby modifying or inhibiting its function. Further work is necessary to resolve these questions.
The amounts of individual VSV polypeptides found in CCX-treated cells varied; L and N (and NS) proteins were decreased whereas M (and G) protein increased in amount despite a reduction in the levels of their transcripts. (There was some interexperimental variability as far as G and NS proteins are concerned. This may have been due to the physiological differences between the BSC-1 cell cultures used.) The precise mechanism of action of CCX, which results in differential accummulation of some VSV proteins, notably M protein, is of interest and needs further investigation. Possible explanations include differential stability of mRNAs and/or preferential translation of some mRNAs; however, a more likely explanation is that the levels of VSV proteins reflect the stability of individual proteins or protein complexes under conditions which restrict virus assembly. The amounts of individual VSV polypeptides observed in CCX-treated cell extracts will reflect two superimposed effects -the first on transcription/translao tion and the second on protein pool stability.
Glycosylation of cellular and VSV glycoproteins was compared in cells treated with CCX, Mon or Tun. CCX and Mon produced a similar small increase in the electrophoretic mobility of VSV glycoprotein G, indicative of an effect of drug late in the maturation of the oligosaccharide chain, possibly in the trans stacks of the Golgi apparatus or in post-Golgi transport vesicles. Tun produced a much larger increase in the electrophoretic mobility of G protein and a complete inhibition of [x'~C]glucosamine labelling of G protein (Fig. 7a, d) . Johnson & Schlesinger (1980) have shown that Mon causes dilation of Golgi apparatus membranes and that transport of the VSV G protein from the Golgi apparatus to the plasma membrane, at which VSV assembly normally occurs (Simons & Garoff, 1980) , is impaired in infected BHK and chick embryo fibroblast cells. Thus, retention of the G protein at the Golgi apparatus suppresses VSV virion assembly. All three drugs, CCX, Mon and Tun, induce the accumulation of the G and M proteins within infected cells. The VSV matrix protein, M, is thought to play a pivotal role in VSV assembly, mediating interactions between the nucleocapsid and G protein (Simons & Garoff, 1980) . We propose that the accumulation of G and M proteins within infected cells treated with CCX is a consequence of a drug-induced restriction of virus assembly.
Since VSV grown in the presence of Mon and Tun retains full infectivity, it is clear that glycosylation of the G protein is not important for infectivity (Gibson et al., 1978) . It follows that loss of virus quality when grown in the presence of CCX is not due to the effect of the drug on glycosylation, but some other function involved in VSV particle assembly. In the case of treatment with CCX or Mort, the inhibited function of the Golgi apparatus which affects particle formation, is not processing of the the glycoprotein, but transport of the G protein to and its insertion into the plasma membrane. This restricts the total number of VSV particles assembled. The transport of G protein in cultures treated with Tun must be affected similarly.
We conclude that VSV replication is extremely sensitive to treatment of host cells with CCX. The result is an at least 100-fold reduction in the number of particles assembled, further exacerbated by loss of quality of progeny virus particles. The known effect of CCX on glycoprotein processing is shown not to be involved in the loss of virus quality, implicating CCX-mediated impairment of another function required for VSV assembly as the cause. The effect of CCX on the transport function of the Golgi apparatus, and the effect of the drug on VSV secondary transcription and possibly on the stability of the protein products is considered to be responsible for the great reduction in the number of particles assembled. Lastly, CCX has a further virucidal effect on suspended mature VSV particles which results in 10% survival after a 24 h period.
